title: [Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
abstract: OBJECTIVE
  To compare the efficacies of pantoprazole and omeprazole-based triple regimens in the treatment of H. pylori infection for 1-week or 2-week.
  
  
  METHODS
  147 patients with H. pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks). The eradication was determined by (13)C-UBT at least 4 weeks after antibiotic therapy.
  
  
  RESULTS
  The eradication rate of H. pylori for 1-week pantoprazole triple regimen and omeprazole triple regimen were 85.7% (42/49) and 76.9% (20/26) respectively (P > 0.05). The eradication rates of H. pylori for 2-weeks and pantoprazole triple regimen and omeprazole triple regimen were 93.9% (31/33) and 82.1% (32/39) for 2-week respectively (P > 0.05).
  
  
  CONCLUSIONS
  The eradication rate of H. pylori in pantoprazole (or omerazole) triple therapy regimen for 2-weeks was higher than 1-week. However there were no significant difference between in these two groups (P > 0.05). There were no significant difference between pantoprazole and omeprazole triple therapy regimen in eradication rate of H. pylori for 1-week or 2-weeks (P > 0.05).
authors.affiliation: Department of Gastroenterology, Peking University First Hospital, Beijing 100034, China.
authors.forename: Meihua
authors.initials: M
authors.lastname: Cui
authors.forename: Fulian
authors.initials: F
authors.lastname: Hu
authors.forename: Hongyu
authors.initials: H
authors.lastname: Jiang
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Zheng
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000150:complications / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D000077402:Pantoprazole; D013454:Sulfoxides / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D008795:Metronidazole; D000658:Amoxicillin; D000077402:Pantoprazole; D009853:Omeprazole